Skip to main content
Premium Trial:

Request an Annual Quote

International Northeast Biotech Corridor Seeks Director

NEW YORK, July 2 - The International Northeast Biotechnology Corridor, a consortium of more than 750 companies from Connecticut to Quebec, will meet next month in the hopes of naming its first director, according to a group official.


The meeting, which will take place at the consortium's headquarters in Fairfield, Maine, also seeks to secure the $250,000 it will cost to function, according to Clyde Dyar, the groups' treasurer.


"Our goals are now to hire a director to lead us and to raise the money we need so we can operate," said Dyar, adding that the consortium has applied to the US Department for Housing and Urban Development for a $50,000 grant.


The INBC was created in 1998 after a gang of governors and premieres from the New England states and eastern Canadian provinces signed an agreement to help "support biotechnology development in the region."


Among its members are Affymetrix, Applied Biosystems, Celera Genomics, Genomics Collaborative, Incyte Genomics, Lion Bioscience, and MIT, according to the Massachusetts Biotechnology Council, an INBC conduit.


Member states include Connecticut, Rhode Island, Massachusetts, Vermont, New Hampshire, Maine, Nova Scotia, New Brunswick, Prince Edward Island, Newfoundland & Labrador, and Quebec, according to INBC.


The framers hope to establish "a regional identity" that would "promote effective cooperation and coordination" between the biotech industry, academia, nonprofits, and governments across state and provincial frontiers, the group says on its web site. More importantly, the founders want the region to be a kind of "Silicon Valley of biotechnology on the east coast," as Dyar put it.


Specifically, the INBC will compile information on regional biotech companies, universities, and R&D efforts; host conferences and "intra-corridor trade/cultural missions;" and "market" the corridor internationally.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.